Anixa Biosciences Inc ANIX
Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology.
Our therapeutics program consists of the development of liraltagene autoleucel ("lira-cel"), a chimeric endocrine receptor-T
cell therapy, which is a novel form of chimeric antigen receptor-T cell ("CAR-T") technology, initially focused on treating
ovarian cancer, that is being developed at our subsidiary, Certainty Therapeutics, Inc. ("Certainty"). Our vaccine programs
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $210.0K | $210.0K | — | $512.0K | — | $250.0K | $1.1M | $362.5K | $300.0K |
| R&D | $5.1M | $6.4M | $4.8M | $6.7M | $6.2M | $4.4M | $5.5M | $6.8M | $1.6M | $1.6M |
| SG&A | $6.6M | $7.4M | $6.3M | $7.2M | $7.1M | $5.6M | $5.7M | $6.9M | $4.4M | $2.7M |
| Total operating expenses | $11.7M | $13.8M | $11.2M | $13.9M | $13.6M | $10.0M | $12.1M | $15.4M | $6.4M | $4.8M |
| Operating income | -$11.7M | -$13.8M | -$11.0M | -$13.9M | -$13.1M | -$10.0M | -$11.9M | -$14.3M | -$6.1M | -$4.5M |
| Interest expense | — | — | — | — | — | — | — | — | $500.5K | $519.9K |
| Pre-tax income | — | — | — | — | — | — | -$11.8M | -$14.2M | -$5.0M | -$5.0M |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | -$13.0M | -$10.0M | -$11.6M | -$14.2M | -$5.0M | -$5.0M |
| EPS, basic | -0.34 | -0.39 | -0.32 | 0.45 | -0.45 | — | — | — | — | — |
| EPS, diluted | -0.34 | -0.39 | -0.32 | 0.45 | -0.45 | -0.45 | -0.59 | -0.79 | -0.58 | -0.57 |
| Shares, diluted (wtd. avg.) | $32.5K | $31.9K | $31.0K | $30.4K | $28.6M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.2M | $1.3M | $915.0K | $12.4M | $29.1M | $6.4M | $3.5M | $3.1M | $3.3M | $2.5M |
| Short-term investments | $13.9M | $18.7M | $22.9M | $17.3M | $6.6M | $2.6M | $2.4M | $2.0M | $3.5M | $750.0K |
| Receivables | — | $173.0K | $270.0K | $46.0K | — | $2.2K | $66.5K | $307.0K | — | — |
| Total current assets | $15.9M | $21.4M | $25.4M | $30.2M | $36.0M | $9.4M | $6.1M | $5.5M | $7.0M | $3.4M |
| Property, plant and equipment | — | — | — | — | — | — | $200.6K | $72.7K | $52.7K | $156.6K |
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M | $9.5M | $6.3M | $6.4M | $8.8M | $5.6M |
| Accounts payable | $165.0K | $525.0K | $206.0K | $265.0K | $136.0K | $232.4K | $585.8K | $582.0K | $480.3K | $373.2K |
| Total current liabilities | $2.0M | $2.5M | $2.0M | $2.0M | $1.3M | $1.2M | $1.5M | $1.3M | $889.5K | $468.8K |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M | $1.2M | — | — | $889.5K | $4.6M |
| Retained earnings | -$251.7M | -$240.8M | -$228.2M | -$218.4M | -$204.8M | -$191.8M | -$181.8M | -$170.2M | -$156.2M | -$151.2M |
| Total equity | $15.2M | $20.0M | $23.4M | $28.2M | $34.8M | $8.3M | $4.8M | $5.2M | $7.9M | $987.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | -$4.9M | -$6.2M | -$4.7M | -$4.3M | -$3.8M | -$3.4M |
| Depreciation and amortisation | — | — | — | — | — | $38.3K | $47.6K | $18.4K | — | — |
| Stock-based compensation | $3.7M | $4.4M | $4.4M | $6.0M | $7.5M | $3.9M | — | — | — | — |
| Capital expenditure | — | — | — | — | — | $15.8K | $175.5K | $38.4K | $30.2K | $146.5K |
| Investing cash flow | $4.9M | $4.3M | -$5.6M | -$10.7M | -$3.9M | -$305.8K | -$525.5K | $1.5M | -$2.7M | $1.5M |
| Financing cash flow | $2.3M | $3.4M | $366.0K | $452.0K | $31.6M | $9.4M | $5.7M | $2.5M | $7.4M | -$2.7K |
| Buybacks | — | $6.0K | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-001845.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |